Rejuve Therapeutics addresses the unmet need in COPD treatment, a disease affecting 20M Americans and 0.5B people globally, with no cure and severe side effects from existing therapies. Rejuve’s unique peptide, delivered via a dry powder inhaler, can slow, stop, and reverse COPD by 80% with minimal side effects. With Phase 1a and 1b data de-risking the current round for full Phase 1 studies, Rejuve is poised to capture significant market share. The Keiretsu Due Diligence report is also available now.
